Albert David Peer Comparison
NSE: ALBERTDAVD | BSE: 524075
₹765.00
As on 18-Nov-2026 13:42IST
Market cap
₹435 Cr
Revenue (TTM)
₹378 Cr
P/E Ratio
15.1
P/B Ratio
1
Div. Yield
0.7 %
| Albert David | Shilpa Medicare | Eris Lifesciences | Caplin Point Lab | Pfizer | |
|---|---|---|---|---|---|
Market cap (₹ Cr) |
435 | 18,124 | 19,088 | 15,849 | 17,415 |
Revenue (₹ Cr) |
378 | 1,842 | 3,330 | 2,383 | 2,654 |
Net Profit (₹ Cr) |
28.75 | 308.62 | 720.77 | 700.18 | 859.38 |
Net Margin (%) |
7.37 | 16.63 | 21.60 | 27.87 | 30.42 |
RoE (%) |
7.07 | 11.81 | 18.93 | 18.40 | 18.58 |
Price to Earnings |
15.13 | 54.52 | 26.98 | 23.00 | 20.26 |
Price-To-Book |
1.03 | 6.57 | 4.61 | 4.06 | 3.97 |
Income Statement (₹ Cr)
| Albert David | Shilpa Medicare | Eris Lifesciences | Caplin Point Lab | Pfizer | |
|---|---|---|---|---|---|
|
Operating Revenue
|
377.96 | 1,841.62 | 3,329.63 | 2,383.13 | 2,654.29 |
|
Total Income
|
389.84 | 1,855.87 | 3,337.47 | 2,512.01 | 2,825.39 |
|
Total Expenditure
|
342.09 | 1,328.95 | 2,168.88 | 1,552.50 | 1,681.39 |
|
EBITDA
|
35.87 | 512.67 | 1,160.75 | 830.63 | 972.90 |
|
Depreciation
|
9.96 | 130.47 | 285.40 | 83.19 | 57.71 |
|
EBIT
|
25.91 | 382.20 | 875.35 | 747.44 | 915.19 |
|
Interest
|
2.24 | 49.12 | 187.51 | 0.94 | 8.91 |
|
Other Income
|
11.88 | 14.25 | 7.84 | 128.88 | 171.10 |
|
Exceptional Items
|
0.00 | 11.73 | -53.14 | 0.00 | 82.90 |
|
Profit before Tax
|
35.55 | 359.06 | 642.54 | 875.38 | 1,160.28 |
|
Provision for Tax
|
6.81 | 50.44 | -78.23 | 175.20 | 300.90 |
|
Profit after Tax
|
28.75 | 308.62 | 720.77 | 700.18 | 859.38 |
Liabilities (₹ Cr)
| Albert David | Shilpa Medicare | Eris Lifesciences | Caplin Point Lab | Pfizer | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
421.89 | 2,757.68 | 4,144.34 | 3,902.45 | 4,385.41 |
|
Minority Interest
|
0.00 | 0.00 | -10.85 | -11.18 | 0.00 |
|
Non-Current Liabilities
|
14.27 | 363.37 | 758.48 | 55.61 | 222.21 |
|
Current Liabilities
|
117.38 | 1,016.50 | 2,681.14 | 366.06 | 685.36 |
|
Total Liabilities
|
636.58 | 3,705.61 | 7,246.72 | 4,037.51 | 4,921.88 |
Assets (₹ Cr)
| Albert David | Shilpa Medicare | Eris Lifesciences | Caplin Point Lab | Pfizer | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
136.75 | 2,763.86 | 5,578.78 | 1,528.69 | 905.21 |
|
Current Assets
|
411.82 | 1,277.15 | 1,800.86 | 2,696.84 | 4,024.56 |
|
Total Assets
|
636.58 | 3,705.61 | 7,246.72 | 4,037.51 | 4,921.88 |
|
Total Debt*
|
28.48 | 657.97 | 2,309.68 | 0.57 | 2.50 |
|
Net Current Assets
|
294.44 | 260.65 | -880.28 | 2,330.78 | 3,339.20 |
|
Contingent Liabilities
|
4.68 | 160.01 | 51.57 | 17.53 | 370.49 |
Cashflow (₹ Cr)
| Albert David | Shilpa Medicare | Eris Lifesciences | Caplin Point Lab | Pfizer | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
-7.66 | 342.18 | 537.99 | 523.24 | 967.57 |
|
Cash Flow from Investing Activities
|
-4.40 | -325.92 | -369.46 | -582.30 | -561.67 |
|
Cash from Financing Activities
|
11.92 | 13.62 | -313.53 | -46.46 | -798.31 |
|
Net Cash Inflow / Outflow
|
-0.14 | 29.88 | -145.00 | -105.52 | -392.41 |
Ratios
Profitability Ratios
| Albert David | Shilpa Medicare | Eris Lifesciences | Caplin Point Lab | Pfizer | |
|---|---|---|---|---|---|
|
ROCE (%)
|
0.83 | 11.43 | 14.47 | 24.97 | 23.39 |
|
ROE (%)
|
7.07 | 11.81 | 18.93 | 18.40 | 18.58 |
|
ROA (%)
|
5.29 | 8.09 | 9.78 | 17.77 | 17.36 |
|
EBIT Margin (%)
|
6.86 | 20.75 | 26.29 | 31.36 | 34.48 |
|
Net Margin (%)
|
7.37 | 16.63 | 21.60 | 27.87 | 30.42 |
|
Cash Profit Margin (%)
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Growth Ratios
| Albert David | Shilpa Medicare | Eris Lifesciences | Caplin Point Lab | Pfizer | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
19.69 | 37.26 | 11.06 | 16.84 | 11.75 |
|
EBIT Growth (%)
|
227.53 | 56.89 | 13.71 | 18.76 | 21.45 |
|
Net Profit Growth (%)
|
290.62 | 127.86 | 60.98 | 17.44 | 2.39 |
|
EPS Growth (%)
|
290.62 | 5.65 | 80.38 | 17.02 | 13.17 |
|
Book Value Growth (%)
|
-0.24 | 9.67 | 36.71 | 26.75 | -0.34 |
Valuation Ratios
| Albert David | Shilpa Medicare | Eris Lifesciences | Caplin Point Lab | Pfizer | |
|---|---|---|---|---|---|
|
Price / Earnings
|
15.29 | 56.81 | 24.70 | 24.83 | 21.87 |
|
Price / Book Value
|
1.04 | 6.50 | 4.55 | 4.38 | 3.98 |
|
Dividend Yield (%)
|
0.65 | 0.07 | 0.00 | 0.36 | 1.97 |
|
EV/EBITDA
|
5.86 | 36.18 | 18.19 | 19.39 | 14.74 |
|
Market Cap (₹ Cr)
|
335.00 | 6,819.66 | 17,980.08 | 11,439.22 | 21,592.90 |
Solvency Ratios
| Albert David | Shilpa Medicare | Eris Lifesciences | Caplin Point Lab | Pfizer | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.00 | 0.08 | 0.10 | 0.00 | 0.00 |
|
Short term debt to equity ratio
|
0.07 | 0.16 | 0.12 | 0.00 | 0.00 |
|
Current Ratio
|
3.51 | 1.26 | 0.67 | 7.37 | 5.87 |
|
Quick Ratio
|
3.05 | 0.82 | 0.49 | 5.88 | 5.23 |
|
Interest Coverage
|
16.85 | 8.31 | 4.43 | 932.26 | 131.22 |
Operating Efficiency Ratios
| Albert David | Shilpa Medicare | Eris Lifesciences | Caplin Point Lab | Pfizer | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
12.66 | 29.09 | 18.98 | 37.32 | 9.10 |
|
Asset Turnover
|
0.70 | 0.48 | 0.45 | 0.60 | 0.54 |
|
Receivable days
|
31.64 | 113.81 | 63.88 | 121.68 | 26.06 |
|
Inventory Days
|
63.07 | 84.76 | 43.27 | 63.83 | 65.95 |
|
Payable days
|
112.32 | 101.94 | 151.85 | 108.28 | 81.01 |
|
Cash Conversion Cycle
|
-17.60 | 96.62 | -44.70 | 77.23 | 11.00 |